跳转到内容

乌美溴铵/维兰特罗

维基百科,自由的百科全书
乌美溴铵/维兰特罗
乌美溴铵(上方)和维兰特罗(下方)
组成
乌美溴铵毒蕈碱拮抗剂英语Muscarinic antagonist
维兰特罗超长效β2激动剂英语Long-acting beta-adrenoceptor agonist
临床资料
商品名英语Drug nomenclatureAnoro Ellipta、Laventair Ellipta
AHFS/Drugs.com专业药物信息
核准状况
怀孕分级
给药途径吸入给药
ATC码
法律规范状态
法律规范
识别信息
CAS号2446159-58-4
KEGG

乌美溴铵/维兰特罗(英语:umeclidinium bromide/vilanterol;商品名:Anoro Ellipta等),是一种用于治疗慢性阻塞性肺病 (COPD) 的固定剂量复方药物。[4][5]它通过吸入给药

最常见的副作用包括上呼吸道感染尿路感染咽炎鼻窦炎鼻咽炎、头痛、咳嗽、口咽疼痛、便秘和口干。[3]

2021年,它是美国第212位最常用处方药物,处方数量超过200万张。[6][7]

参考资料

[编辑]
  1. ^ Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. (原始内容存档于2023-04-10). 
  2. ^ Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC). (emc). 7 October 2019 [29 October 2020]. (原始内容存档于2021-08-29). 
  3. ^ 3.0 3.1 Anoro Ellipta EPAR. European Medicines Agency (EMA). 17 September 2018 [28 October 2020]. (原始内容存档于2020-11-11).  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Therapeutic Advances in Respiratory Disease. December 2013, 7 (6): 311–9. PMID 24004659. S2CID 5744282. doi:10.1177/1753465813499789. 
  5. ^ FDA Approves Umeclidinium and Vilanterol Combo for COPD. Medscape. 18 December 2013 [2024-03-07]. (原始内容存档于2017-09-24). 
  6. ^ The Top 300 of 2021. ClinCalc. [14 January 2024]. (原始内容存档于15 January 2024). 
  7. ^ Umeclidinium; Vilanterol - Drug Usage Statistics. ClinCalc. [14 January 2024]. (原始内容存档于2024-02-29).